This substance is a potent platelet aggregation inhibitor that works by inhibiting the GP IIb/IIIa receptor on the platelet surface, the final step in platelet aggregation, thereby reducing the formation of thrombotic occlusions in blood vessels. It is used in patients with acute coronary syndromes, such as acute myocardial infarction or unstable angina from coronary artery stenosis, particularly in cases undergoing percutaneous coronary intervention (PCI) to prevent thrombotic complications during high-risk periods. It is classified as a hospital-only medication under close medical supervision due to side effects such as increased bleeding risk.